These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30174470)

  • 1. Prostate-Specific Membrane Antigen PET Imaging in Prostate Cancer: Opportunities and Challenges.
    Oh SW; Cheon GJ
    Korean J Radiol; 2018; 19(5):819-831. PubMed ID: 30174470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
    Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
    Arsenault F; Beauregard JM; Pouliot F
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic Sites' Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review.
    Mattana F; Muraglia L; Rajwa P; Zattoni F; Marra G; Chiu PKF; Heidegger I; Kasivisvanathan V; Kesch CV; Olivier J; Preisser F; Thibault C; Valerio M; van den Bergh RCN; Gandaglia G; Ceci F;
    Eur Urol Oncol; 2023 Apr; 6(2):128-136. PubMed ID: 36804735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis.
    Perera M; Papa N; Roberts M; Williams M; Udovicich C; Vela I; Christidis D; Bolton D; Hofman MS; Lawrentschuk N; Murphy DG
    Eur Urol; 2020 Apr; 77(4):403-417. PubMed ID: 30773328
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis.
    Subiela JD; Gomis Sellés E; Maldonado A; Lopez Campos F; Aumatell Ovide J; Ajuria Illarramendi O; González-Padilla DA; Gajate P; Ortega Polledo LE; Alonso Y Gregorio S; Guerrero-Ramos F; Gómez Dos Santos V; Rodríguez-Patrón R; Calais J; Kishan AU; Burgos Revilla FJ; Couñago F
    Clin Oncol (R Coll Radiol); 2023 Dec; 35(12):e676-e688. PubMed ID: 37802722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Magnetic Resonance Imaging in Primary and Recurrent Prostate Cancer: A Systematic Review of the Literature.
    Manfredi C; Fernández-Pascual E; Arcaniolo D; Emberton M; Sanchez-Salas R; Artigas Guix C; Bianco F; Cathcart P; Murphy DG; Couñago F; Martínez-Ballesteros C; Verze P; Martínez-Salamanca JI
    Eur Urol Focus; 2022 Jul; 8(4):942-957. PubMed ID: 34538633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
    Ferraro DA; Burger IA
    Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical efficacy of PSMA PET/MRI in biochemically recurrent prostate cancer compared with standard of care imaging modalities and confirmatory histopathology: results of a single-centre, prospective clinical trial.
    Joshi A; Roberts MJ; Perera M; Williams E; Rhee H; Pryor D; Lehman M; Heathcote P; Wood S; Coucher J; Gustafson S; Miles K; Vela I
    Clin Exp Metastasis; 2020 Aug; 37(4):551-560. PubMed ID: 32519046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence.
    Bianchi L; Castellucci P; Farolfi A; Droghetti M; Artigas C; Leite J; Corona P; Shagera QA; Moreira R; González C; Queiroz M; de Galiza Barbosa F; Schiavina R; Deandreis D; Fanti S; Ceci F
    Eur Urol Oncol; 2023 Feb; 6(1):41-48. PubMed ID: 34933814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific membrane antigen positron emission tomography in prostate cancer: a step toward personalized medicine.
    Bouchelouche K; Choyke PL
    Curr Opin Oncol; 2016 May; 28(3):216-21. PubMed ID: 26967720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
    Barrio M; Fendler WP; Czernin J; Herrmann K
    Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prostate-specific membrane antigen positron emission tomography (PSMA PET) for urologists-when and which tracer?].
    Berliner C; Kesch C; Fendler WP; Eiber M; Maurer T
    Urologe A; 2022 Apr; 61(4):384-391. PubMed ID: 35138414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study between
    Wong HS; Leung J; Bartholomeusz D; Sutherland P; Le H; Nottage M; Iankov I; Chang JH
    J Med Imaging Radiat Oncol; 2018 Dec; 62(6):816-822. PubMed ID: 30152050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron Emission Tomography and Whole-body Magnetic Resonance Imaging for Metastasis-directed Therapy in Hormone-sensitive Oligometastatic Prostate Cancer After Primary Radical Treatment: A Systematic Review.
    Farolfi A; Hadaschik B; Hamdy FC; Herrmann K; Hofman MS; Murphy DG; Ost P; Padhani AR; Fanti S
    Eur Urol Oncol; 2021 Oct; 4(5):714-730. PubMed ID: 33750684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific membrane antigen positron emission tomography in the management of recurrent prostate cancer.
    Afaq A; Bomanji J
    Br Med Bull; 2018 Dec; 128(1):37-48. PubMed ID: 30272121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single Lesion on Prostate-specific Membrane Antigen-ligand Positron Emission Tomography and Low Prostate-specific Antigen Are Prognostic Factors for a Favorable Biochemical Response to Prostate-specific Membrane Antigen-targeted Radioguided Surgery in Recurrent Prostate Cancer.
    Horn T; Krönke M; Rauscher I; Haller B; Robu S; Wester HJ; Schottelius M; van Leeuwen FWB; van der Poel HG; Heck M; Gschwend JE; Weber W; Eiber M; Maurer T
    Eur Urol; 2019 Oct; 76(4):517-523. PubMed ID: 30987843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.